ArticleFrontiers in immunology2026
Standardized pressure provocation as an objective clinical marker of omalizumab response in delayed pressure urticaria: an open-label, real-life, prospective cohort.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Delayed pressure urticaria (DPU) is a disabling chronic inducible urticaria characterized by delayed painful swelling after sustained pressure. Evidence-based therapeutic options remain limited, and omalizumab is frequently used off-label in antihistamine-refractory cases despite scarce prospective DPU-specific data with objective provocation testing. Methods: In a prospective, single-center, open-label cohort, adults with dermographometer-confirmed DPU refractory to licensed or high-dose second-generation H1-antihistamines received omalizumab 300 mg subcutaneously every 4 weeks. Patients were contacted daily during the first week after the initial dose and deliberately exposed to their typical pressure triggers to define time to complete symptom control. Baseline clinico-demographic characteristics, laboratory parameters, atopic status and comorbidities were recorded, and potential predictors of time to response were explored by univariate regression. Results: Forty-two patients were included (61.9% female; mean age at diagnosis 46.0 ± 14.0 years). Aeroallergen sensitization was present in 52.4% and clinically documented allergic disease in 26.2%; autoimmune thyroid disease was recorded in 33.3%. The DPU phenotype frequently involved soles and/or palms (54.8%), and angioedema (28.6%) and systemic symptoms (26.2%) were common. After the first omalizumab dose, 41/42 patients (97.6%) achieved complete symptom control within 96 hours (median 24 hours); 57.1% responded within 24 hours and 83.3% within 48 hours. One patient achieved only partial control. No serious adverse events or need for rescue systemic corticosteroids were observed. Time to response was not associated with sex, age, baseline total IgE, aeroallergen sensitization, atopic background, or autoimmune thyroid disease. Conclusion: In dermographometer-confirmed, antihistamine-refractory DPU, omalizumab was associated with a rapid clinical remission in almost all patients, typically within 24-48 hours, independent of baseline IgE and common comorbidities. Standardized pressure provocation testing provides objective confirmation of DPU and a pragmatic approach for diagnosis and real-world monitoring of therapeutic response in DPU. Given the open-label, uncontrolled design, these findings should be confirmed in larger multicenter controlled studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.